The FDA last week issued warning letters against a handful of companies flagging violations regarding the promotion and sale of unapproved weight-loss drugs, including unlicensed versions of the blockbuster therapies semaglutide and tirzepatide
Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics
doi:10.1016/j.bbadis.2013.05.018 Godos J, Romano GL, Gozzo L, et al
Q2: Is Pinealon FDA-approved